

# Michelle L Hermiston

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8038190/publications.pdf>

Version: 2024-02-01

56  
papers

4,164  
citations

279798

23  
h-index

206112

48  
g-index

57  
all docs

57  
docs citations

57  
times ranked

7087  
citing authors

#	ARTICLE	IF	CITATIONS
1	The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. <i>Nature</i> , 2012, 481, 157-163.	27.8	1,430
2	CD45: A Critical Regulator of Signaling Thresholds in Immune Cells. <i>Annual Review of Immunology</i> , 2003, 21, 107-137.	21.8	737
3	Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: Recommendations from the North American Consortium for Histiocytosis (NACHO). <i>Pediatric Blood and Cancer</i> , 2019, 66, e27929.	1.5	220
4	Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia. <i>Blood</i> , 2015, 125, 1759-1767.	1.4	189
5	Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2018, 131, 995-999.	1.4	170
6	CD45, CD148, and Lyp/Pep: critical phosphatases regulating Src family kinase signaling networks in immune cells. <i>Immunological Reviews</i> , 2009, 228, 288-311.	6.0	159
7	<i>PTPN22</i> Deficiency Cooperates with the CD45 E613R Allele to Break Tolerance on a Non-Autoimmune Background. <i>Journal of Immunology</i> , 2009, 182, 4093-4106.	0.8	117
8	MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia. <i>Blood</i> , 2015, 126, 2202-2212.	1.4	88
9	Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study. <i>Leukemia</i> , 2018, 32, 2316-2325.	7.2	88
10	Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report. <i>Journal of Clinical Oncology</i> , 2022, 40, 945-955.	1.6	79
11	Reciprocal regulation of lymphocyte activation by tyrosine kinases and phosphatases. <i>Journal of Clinical Investigation</i> , 2002, 109, 9-14.	8.2	69
12	T-cell activation profiles distinguish hemophagocytic lymphohistiocytosis and early sepsis. <i>Blood</i> , 2021, 137, 2337-2346.	1.4	63
13	Lymphoblastic lymphoma in children and adolescents: review of current challenges and future opportunities. <i>British Journal of Haematology</i> , 2019, 185, 1158-1170.	2.5	60
14	The Juxtamembrane Wedge Negatively Regulates CD45 Function in B Cells. <i>Immunity</i> , 2005, 23, 635-647.	14.3	56
15	Donor Myocardial Infarction Impairs the Therapeutic Potential of Bone Marrow Cells by an Interleukin-1 Mediated Inflammatory Response. <i>Science Translational Medicine</i> , 2011, 3, 100ra90.	12.4	53
16	JAK/STAT pathway inhibition sensitizes CD8 T cells to dexamethasone-induced apoptosis in hyperinflammation. <i>Blood</i> , 2020, 136, 657-668.	1.4	50
17	Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy. <i>Blood Advances</i> , 2022, 6, 1961-1968.	5.2	47
18	Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 2106-2118.	1.6	45

#	ARTICLE	IF	CITATIONS
19	Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children's Oncology Group AALL0434. <i>Journal of Clinical Oncology</i> , 2020, 38, 3062-3070.	1.6	42
20	Manipulating DNA damage-response signaling for the treatment of immune-mediated diseases. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E4782-E4791.	7.1	40
21	Glucocorticoids paradoxically facilitate steroid resistance in T cell acute lymphoblastic leukemias and thymocytes. <i>Journal of Clinical Investigation</i> , 2020, 130, 863-876.	8.2	36
22	Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report. <i>Blood Advances</i> , 2022, 6, 600-610.	5.2	32
23	A practical approach to the evaluation of the anemic child. <i>Pediatric Clinics of North America</i> , 2002, 49, 877-891.	1.8	26
24	Disease Burden Impacts Outcomes in Pediatric and Young Adult B-Cell Acute Lymphoblastic Leukemia after Commercial Tisagenlecleucel: Results from the Pediatric Real World CAR Consortium (PRWCC). <i>Blood</i> , 2020, 136, 14-15.	1.4	25
25	IFN- $\gamma$ signature in the plasma proteome distinguishes pediatric hemophagocytic lymphohistiocytosis from sepsis and SIRS. <i>Blood Advances</i> , 2021, 5, 3457-3467.	5.2	23
26	Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 4251-4255.	5.2	20
27	Differential impact of the CD45 juxtamembrane wedge on central and peripheral T cell receptor responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 546-551.	7.1	19
28	Decitabine and vorinostat with FLAG chemotherapy in pediatric relapsed/refractory AML: Report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium. <i>American Journal of Hematology</i> , 2022, 97, 613-622.	4.1	19
29	Calming the storm in HLH. <i>Blood</i> , 2019, 134, 103-104.	1.4	17
30	Ibrutinib significantly inhibited Bruton's tyrosine kinase (BTK) phosphorylation, in-vitro proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model. <i>Oncolmmunology</i> , 2019, 8, e1512455.	4.6	17
31	CRLF2 rearrangement in Ph-like acute lymphoblastic leukemia predicts relative glucocorticoid resistance that is overcome with MEK or Akt inhibition. <i>PLoS ONE</i> , 2019, 14, e0220026.	2.5	16
32	Digenic Inheritance: Evidence and Gaps in Hemophagocytic Lymphohistiocytosis. <i>Frontiers in Immunology</i> , 2021, 12, 777851.	4.8	12
33	The Structural Wedge Domain of the Receptor-like Tyrosine Phosphatase CD45 Enforces B Cell Tolerance by Regulating Substrate Specificity. <i>Journal of Immunology</i> , 2013, 190, 2527-2535.	0.8	11
34	B cells drive lymphocyte activation and expansion in mice with the CD45 wedge mutation and Fas deficiency. <i>Journal of Experimental Medicine</i> , 2008, 205, 2755-2761.	8.5	10
35	Cranial Radiation Can be Eliminated in Most Children with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Bortezomib Potentially Improves Survival in Children with T-Cell Lymphoblastic Lymphoma (T-L): Results of Children's Oncology Group (COG) Trial AALL1231. <i>Blood</i> , 2020, 136, 11-12.	1.4	10
36	Real-World Treatment of Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Using Tisagenlecleucel That Is out of Specification for Commercial Release. <i>Blood</i> , 2020, 136, 42-44.	1.4	8

#	ARTICLE	IF	CITATIONS
37	Unbiased Modifier Screen Reveals That Signal Strength Determines the Regulatory Role Murine TLR9 Plays in Autoantibody Production. <i>Journal of Immunology</i> , 2015, 194, 3675-3686.	0.8	7
38	Age-Related Impaired Efficacy of Bone Marrow Cell Therapy for Myocardial Infarction Reflects a Decrease in B Lymphocytes. <i>Molecular Therapy</i> , 2018, 26, 1685-1693.	8.2	7
39	The epigenome in pediatric acute lymphoblastic leukemia: drug resistance and therapeutic opportunities. , 2019, 2, 313-325.		6
40	Inhibition of the Sec61 translocon overcomes cytokine-induced glucocorticoid resistance in T-cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2022, , .	2.5	6
41	Targeting childhood, adolescent and young adult non-Hodgkin lymphoma: therapeutic horizons. <i>British Journal of Haematology</i> , 2016, 173, 625-636.	2.5	5
42	High-Throughput Flow Cytometry Identifies Small-Molecule Inhibitors for Drug Repurposing in T-ALL. <i>SLAS Discovery</i> , 2018, 23, 732-741.	2.7	5
43	Out-of-specification tisagenlecleucel does not compromise safety or efficacy in pediatric acute lymphoblastic leukemia. <i>Blood</i> , 2021, 138, 2138-2142.	1.4	5
44	HESTER: A Phase II Study Evaluating Efficacy and Safety of Tisagenlecleucel Reinfusion in Pediatric and Young Adult Patients with Acute Lymphoblastic Leukemia Experiencing Loss of B-Cell Aplasia. <i>Blood</i> , 2020, 136, 23-24.	1.4	4
45	The bone marrow microenvironment as a mediator of chemoresistance in acute lymphoblastic leukemia. , 2019, 2, 1164-1177.		4
46	Perceptions of specialty palliative care and its role in pediatric stem cell transplant: A multidisciplinary qualitative study. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29424.	1.5	3
47	ZUMA-4: A Phase 1/2 Multicenter Study of KTE-X19 in Pediatric and Adolescent Patients With Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma. <i>Blood</i> , 2020, 136, 42-42.	1.4	3
48	Subcutaneous panniculitis-like T-cell lymphomas with homozygous inheritance of <i>HAVCR2</i> mutations in Vietnamese pedigrees. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29292.	1.5	2
49	Children's Oncology Group (COG) AALL0434: Successful Disease Control without Cranial Radiation in Newly Diagnosed T Lymphoblastic Lymphoma (T-LL). <i>Blood</i> , 2018, 132, 1000-1000.	1.4	2
50	Double trouble for Langerhans cell histiocytosis. <i>Blood</i> , 2021, 137, 1705-1706.	1.4	1
51	Intensification of Chemotherapy Using a Modified BFM Backbone for Children, Adolescents and Young Adults with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) Identifies Highly Chemorefractory Patients Who Benefit from Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2021, 138, 3487-3487.	1.4	1
52	Distinct Signaling Profiles and Drug Responses Identify Subpopulations of Pediatric T-Cell Acute Lymphoblastic Leukemia and Lymphoma Patients.. <i>Blood</i> , 2009, 114, 1595-1595.	1.4	0
53	Aberrant MAPK and PI3K Signaling Contribute to Chemotherapy Resistance in T Cell Acute Lymphoblastic Leukemia by Altering the Balance of Apoptosis Mediators.. <i>Blood</i> , 2011, 118, 3490-3490.	1.4	0
54	Glucocorticoids Paradoxically Induce Intrinsic Steroid Resistance through a STAT5-Mediated Survival Mechanism in T-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018, 132, 913-913.	1.4	0

#	ARTICLE	IF	CITATIONS
55	Protein Translocation Inhibitors Overcome Cytokine-Induced Glucocorticoid Resistance in T-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2019, 134, 805-805.	1.4	0
56	Concurrent Subcutaneous Panniculitis-like T-Cell Lymphoma and B-Cell Acute Lymphoblastic Leukemia in 2 Pediatric Patients. <i>Journal of Pediatric Hematology/Oncology</i> , 2021, 43, e791-e794.	0.6	0